Page URL:

Special rules for US gene therapy trials relaxed

20 August 2018
Appeared in BioNews 963

US gene therapy trials will now be treated like other clinical trials, as the National Institutes for Health (NIH) step back from regulating them. 

Although the change removes one layer of regulation, gene therapy trials will still need to meet US Food and Drug Administration (FDA) safety and ethical requirements and, as with all clinical research, regulatory approvals must be in place before a gene therapy trial can proceed.  

'There is no longer sufficient evidence to claim that the risks of gene therapy are entirely unique or unpredictable – or that the field requires special oversight that falls outside our existing framework for ensuring safety', wrote NIH Director Dr Francis Collins and FDA Commissioner Dr Scott Gottlieb in the The New England Journal of Medicine.  

Gene therapies, used to introduce a new gene, delete or edit abnormal DNA, became a safety concern following a teen's death in 1999. The field has advanced significantly especially in recent years, encompassing genome editing approaches such as CRISPR/Cas9. The FDA approved three gene therapies for clinical use in the USA in 2017 (see BioNews 916)

Previously trial protocols, annual reports, and reports of serious adverse events had to be submitted to both the NIH and the FDA, leading to duplicated work and increased administrative burden on researchers. The NIH have, therefore, set out new plans to simplify the safety management in US gene therapy trials by introducing changes to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

As oversight of gene therapy trial will now be handled by the FDA, the NIH is calling on the Recombinant DNA Advisory Committee (RAC) to re-focus its attention on the 'scientific, safety, and ethical issues associated with emerging biotechnology'. 

However, not everyone supports the changes. 

'This is not the right time to be making any moves based on the idea that we know what the risks are,' said Professor Mildred Cho, a biomedical ethicist at Stanford University and a member of RAC. 'We really don't understand how [gene therapies] work.'

Officials remove special rules for gene therapy experiments
Associated Press |  16 August 2018
Statement on modernizing human gene therapy oversight
The National Institutes of Health |  16 August 2018
The Next Phase of Human Gene-Therapy Oversight
New England Journal of Medicine |  15 August 2018
The NIH loosens its grip on gene therapy trials
The Scientist |  16 August 2018
20 December 2021 - by Francesca Gavins 
Former head of the Human Genome Project, physician and geneticist, Francis Collins has resigned from his role of the head of the US National Institutes of Health in Bethesda, Maryland...
18 December 2017 - by Dr Sam Sherratt 
A new gene therapy for haemophilia A has exceeded expectations in a recent clinical trial...
20 November 2017 - by Martha Henriques 
The US Food and Drug Administration has announced a fast-track review process for gene therapies and other regenerative medicine treatments...
4 September 2017 - by Meetal Solanki 
The world's first cancer treatment which uses a patient's own genetically modified immune cells has been approved...
14 February 2000 - by BioNews 
Legislation to tighten up the regulation of federally funded human gene therapy trials was introduced into the US house of representatives last week. The move follows concerns that deaths and serious deterioration of patients involved in gene therapy experiments are not being reported adequately. Researchers are supposed to report any...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.